ReviewRheumatic diseases clinics of North America2013
Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.
Review in Rheumatic diseases clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Impaired Brachial Artery Reactivity in Young Adults With Clinically Quiescent Juvenile Dermatomyositis.ACR open rheumatology · 2025Article
- Article
- Juvenile Dermatomyositis in a Two-Year-Old Yemeni Girl in a Resource-Limited Setting: A Case Report.Cureus · 2025Article
- When a Child Refuses to Play: A Rare Myopathy.Cureus · 2024Article
- Diagnostic Value of Whole-Body MRI in Pediatric Patients with Suspected Rheumatic Diseases.Medicina (Kaunas, Lithuania) · 2024Article
- Familial clustering of dysbiotic oral and fecal microbiomes in juvenile dermatomyositis.Scientific reports · 2024Observational
- Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.Pediatric rheumatology online journal · 2023Article
- Implementation of an embedded behavioral health care model in a pediatric rheumatology subspecialty juvenile myositis clinic.Frontiers in psychiatry · 2023Article
- Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus.Clinical rheumatology · 2022Article
- Periorbital rash and scaly plaques in a 13-year-old boy.JAAD case reports · 2022Article
- Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: a case report with literature review.BMC pediatrics · 2021Review
- Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.Rheumatic diseases clinics of North America · 2021Review
- Atypical Power Doppler Ultrasound Findings in Juvenile Idiopathic Inflammatory Myositis (JIIM) Flare.Cureus · 2021Article
- Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.Acta neuropathologica communications · 2020Article
- Child with fever, rash, and abnormal gait.Journal of the American College of Emergency Physicians open · 2020Article
- Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.World journal of pediatrics : WJP · 2020Review
- Long-term outcomes in Juvenile Myositis patients.Seminars in arthritis and rheumatism · 2020Article
- Outcome of children with systemic rheumatic diseases admitted to pediatric intensive care unit: An experience of a tertiary hospital.International journal of pediatrics & adolescent medicine · 2019Article
- Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies.Frontiers in neurology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This review updates recent trends in the classification of the juvenile idiopathic inflammatory myopathies (JIIM) and the emerging standard of treatment of the most common form of JIIM, juvenile dermatomyositis. The JIIM are rare, heterogeneous autoimmune diseases that share chronic muscle inflammation and weakness. A growing spectrum of clinicopathologic groups and serologic phenotypes defined by the presence of myositis autoantibodies are now recognized, each with differing demographics, clinical manifestations, laboratory findings, and prognoses. Although daily oral corticosteroids remain the backbone of treatment, disease-modifying anti-rheumatic drugs are almost always used adjunctively and biologic therapies may benefit patients with recalcitrant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.